Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Neoplasms 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × Introns × Genitourinary × Clear all
NCT00445523 2016-03-17

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

The Methodist Hospital Research Institute

Phase 2 Completed
28 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00293527 2013-05-23

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡